Physician

Charles Robert Claydon, MD

According to 2025 Medicare claims, Charles Claydon, MD (NPI: 1003884156) practices family practice in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Dearborn, IN. This provider's primary affiliated billing organization is SUMMIT MEDICAL GROUP, INC (NPI: 1750343216; TIN: 611300608) and primary practice location at 47025-7791. Claydon is affiliated with the Healthcare Solutions Network (ACO ID: A3283), participating under the MSSP model.

Claydon's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 163 traditional Medicare patients, billed 1,084 HCPCS/CPT codes, and received $68,744 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 3,953 prescription claims across 291 beneficiaries totaling $425,642 in drug costs, led by Eliquis (Apixaban). 2023 DME data shows 24 claims. Open Payments data shows 1 records totaling $18. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $223,116 to $425,642. In contrast, DME billing represents a smaller volume and rose steadily, from $220 to $1,738.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	204	1,053	$63,015
2016	212	1,054	$65,045
2017	227	1,228	$71,402
2018	217	1,247	$70,720
2019	211	1,139	$65,950
2020	197	1,092	$61,369
2021	202	1,124	$80,087
2022	194	1,030	$75,506
2023	171	893	$69,665
2024	163	1,084	$68,744

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	215	3,204	$223,116
2016	229	3,345	$221,213
2017	213	3,535	$233,381
2018	226	3,680	$240,374
2019	243	3,643	$242,304
2020	253	3,744	$293,191
2021	264	3,830	$280,513
2022	273	3,964	$334,527
2023	276	3,805	$384,256
2024	291	3,953	$425,642

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	31	64	$923
2016	35	84	$852
2017	17	65	$577
2018	16	52	$480
2019	N/R	30	$256
2020	N/R	49	$551
2021	N/R	28	$190
2022	N/R	59	$1,428
2023	N/R	24	$923
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	99	99	$125
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	148	420	$78
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	47	64	$59
G0008	Administration of influenza virus vaccine	29	29	$30
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	111	222	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	57	2,838	$55,115
Trulicity	Dulaglutide	19	1,428	$44,109
Jardiance	Empagliflozin	36	2,124	$43,370
Ozempic	Semaglutide	28	1,176	$39,774
Mounjaro	Tirzepatide	11	700	$25,762

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$18	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Charles Robert Claydon, MD?

Tedicare shows public-source Medicare data for Charles Robert Claydon, MD (NPI 1003884156), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Charles Robert Claydon, MD have ACO affiliation data?

Charles Robert Claydon, MD is shown with ACO affiliation data for Healthcare Solutions Network (MSSP, ACO ID A3283).

What billing organization is linked to Charles Robert Claydon, MD?

Charles Robert Claydon, MD is linked to SUMMIT MEDICAL GROUP, INC (billing NPI 1750343216) in the available physician profile data.

Does Charles Robert Claydon, MD have Open Payments data?

Charles Robert Claydon, MD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.